Gyre Therapeutics Inc. has published a document detailing the Phase 3 trial results of Hydronidone (F351) in treating liver fibrosis associated with chronic hepatitis B. The document includes information on the achievement of primary and secondary endpoints, a favorable safety profile, and future clinical and regulatory plans. The full document can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.